Marquele-Oliveira Franciane, Torres Elina Cassia, Barud Hernane da Silva, Zoccal Karina Furlani, Faccioli Lúcia Helena, Hori Juliana I, Berretta Andresa Aparecida
Laboratório de Pesquisa, Desenvolvimento e Inovação, Apis Flora Indl. Coml. Ltda., Ribeirão Preto, SP, Brazil.
Laboratório de Pesquisa, Desenvolvimento e Inovação, Apis Flora Indl. Coml. Ltda., Ribeirão Preto, SP, Brazil.
J Pharm Biomed Anal. 2016 May 10;123:195-204. doi: 10.1016/j.jpba.2016.01.045. Epub 2016 Jan 28.
The control and treatment of Leishmaniasis, a neglected and infectious disease affecting approximately 12 million people worldwide, are challenging. Leishmania parasites multiply intracellularly within macrophages located in deep skin and in visceral tissues, and the currently employed treatments for this disease are subject to significant drawbacks, such as resistance and toxicity. Thus, the search for new Leishmaniasis treatments is compulsory, and Ocotea duckei Vattimo, a plant-derived product from the biodiverse Brazilian flora, may be a promising new treatment for this disease. In this regard, the aim of this work was to develop and characterize a delivery system based on solid lipid nanoparticles (SLN) that contain the liposoluble lignan fraction (LF) of Ocotea duckei Vattimo, which targets the Leishmania phagolysosome of infected macrophages. LF-loaded SLNs were obtained via the hot microemulsion method, and their physical and chemical properties were comprehensively assessed using PCS, AFM, SEM, FT-IR, DSC, HPLC, kinetic drug release studies, and biological assays. The size of the developed delivery system was 218.85±14.2 nm, its zeta potential was -30 mV and its entrapment efficiency (EE%) was high (the EEs% of YAN [yangambin] and EPI-YAN [epi-yangambin] markers were 94.21±0.40% and 94.20±0.00%, respectively). Microscopy, FT-IR and DSC assays confirmed that the delivery system was nanosized and indicated a core-shell encapsulation model, which corroborated the measured kinetics of drug release. The total in vitro release rates of YAN and EPI-YAN in buffer (with sink conditions attained) were 29.6±8.3% and 34.3±8.9%, respectively, via diffusion through the cellulose acetate membrane of the SLN over a period of 4 h. After 24 h, the release rates of both markers reached approximately 45%, suggesting a sustained pattern of release. Mathematical modeling indicated that both markers, YAN and EPI-YAN, followed matrix diffusion-based release kinetics (Higuchi's model) with an estimated diffusion coefficient (D) of 1.3.10(-6) cm(2)/s. The LF-loaded SLNs were non-toxic to murine macrophages (20-80 μg mL(-1) range) and exerted a prominent anti-leishmanial effect (20 μg mL(-1)). These data suggest this new and well-characterized lipid nanoparticle delivery system safely and effectively kills Leishmania and warrants further clinical investigation.
利什曼病是一种被忽视的传染病,全球约有1200万人受其影响,对其进行控制和治疗具有挑战性。利什曼原虫寄生于深层皮肤和内脏组织的巨噬细胞内并在其中繁殖,目前用于治疗该疾病的方法存在显著缺陷,如耐药性和毒性。因此,寻找治疗利什曼病的新方法势在必行,而奥氏樟(Ocotea duckei Vattimo)是一种源自巴西生物多样性丰富的植物的产物,可能是治疗该疾病的一种有前景的新方法。在这方面,本研究的目的是开发并表征一种基于固体脂质纳米粒(SLN)的递送系统,该系统包含奥氏樟的脂溶性木脂素组分(LF),可靶向感染巨噬细胞中的利什曼原虫吞噬溶酶体。通过热微乳法制备了负载LF的SLN,并使用电位分析法(PCS)、原子力显微镜(AFM)、扫描电子显微镜(SEM)、傅里叶变换红外光谱(FT-IR)、差示扫描量热法(DSC)、高效液相色谱(HPLC)、药物释放动力学研究和生物学测定对其物理和化学性质进行了全面评估。所开发的递送系统粒径为218.85±14.2 nm,zeta电位为 -30 mV,包封率(EE%)较高(严贝因[yangambin]和表严贝因[epi-yangambin]标记物的EE%分别为94.21±0.40%和94.20±0.00%)。显微镜、FT-IR和DSC分析证实该递送系统为纳米级,并表明其为核壳包封模型,这与测得的药物释放动力学相符。在缓冲液中(达到漏槽条件),通过SLN的醋酸纤维素膜扩散4小时后,严贝因和表严贝因的体外总释放率分别为29.6±8.3%和34.3±8.9%。24小时后,两种标记物的释放率均达到约45%,表明释放模式具有持续性。数学模型表明,严贝因和表严贝因这两种标记物均遵循基于基质扩散的释放动力学(Higuchi模型),估计扩散系数(D)为1.3×10(-6) cm(2)/s。负载LF的SLN对小鼠巨噬细胞无毒(浓度范围为20 - 80 μg mL(-1)),并具有显著的抗利什曼原虫作用(20 μg mL(-1))。这些数据表明,这种新的且特性良好的脂质纳米粒递送系统能够安全有效地杀死利什曼原虫,值得进一步开展临床研究。